Accordingly, dual binding site inhibitors able to interact with both the CAS and PAS will be more promising for treating AD, as they can not only improve cognition by inhibiting AChE, but also provide additional benefit through reducing the Aβ aggregation induced by AChE. Here, ACHE is linked to Alzheimer disease.